Inventor
HAGEDORN PETER
DK18 patents
⚠️ This page may combine multiple inventors who share the name “HAGEDORN PETER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HOFFMANN LA ROCHE
9 patentsUS10799523B2Oct 13, 2020
Tau antisense oligomers and uses thereof
HOFFMANN LA ROCHE3 citations71
US11279929B2Mar 22, 2022
Oligonucleotides for modulating Tau expression
HOFFMANN LA ROCHE3 citations69
US11077132B2Aug 3, 2021
Tau antisense oligomers and uses thereof
HOFFMANN LA ROCHE0 citations61
US12163131B2Dec 10, 2024
Oligonucleotides for modulating Tau expression
HOFFMANN LA ROCHE0 citations59
US11753640B2Sep 12, 2023
Oligonucleotides for modulating Tau expression
HOFFMANN LA ROCHE0 citations59
US11286485B2Mar 29, 2022
Oligonucleotides for modulating ATXN2 expression
HOFFMANN LA ROCHE0 citations56
US11066669B2Jul 20, 2021
Oligonucleotides for modulating ATXN2 expression
HOFFMANN LA ROCHE0 citations55
US11542501B2Jan 3, 2023
Antisense oligonucleotides targeting ATXN3
HOFFMANN LA ROCHE1 citations51
US10519450B2Dec 31, 2019
Antisense oligonucleotides for modulating HTRA1 expression
HOFFMANN LA ROCHE0 citations44
BRISTOL MYERS SQUIBB CO
6 patentsUS11359197B2Jun 14, 2022
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
BRISTOL MYERS SQUIBB CO4 citations81
US11447775B2Sep 20, 2022
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
BRISTOL MYERS SQUIBB CO3 citations70
US11058767B2Jul 13, 2021
CAMK2D antisense oligonucleotides and uses thereof
BRISTOL MYERS SQUIBB CO0 citations60
US12180478B2Dec 31, 2024
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
BRISTOL MYERS SQUIBB CO0 citations59
US11761951B2Sep 19, 2023
Methods of selecting therapeutic molecules
BRISTOL MYERS SQUIBB CO0 citations50
US12241065B2Mar 4, 2025
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
BRISTOL MYERS SQUIBB CO0 citations49